Eliem Therapeutics | PREM14A:并购处分代理声明
Eliem Therapeutics | SC 13D/A:超过5%持股股东披露文件(修正)-RA Capital Management, L.P.(45.3%),Peter Kolchinsky(45.3%)等
Eliem Therapeutics | SC 13D/A:超过5%持股股东披露文件(修正)
Eliem Therapeutics | 10-Q:季度报表
Eliem Therapeutics | SC 13G:超过5%持股股东披露文件-Affinity Healthcare Fund, LP (EIN(6.02%),Affinity Asset Advisors, LLC (EIN(6.02%)
Eliem Therapeutics | 10-K/A:年度报表(修正版)
Eliem Therapeutics | SC 13D/A:超过5%持股股东披露文件(修正)-RA Capital Management, L.P.(47.5%),Peter Kolchinsky(47.5%)等
Eliem Therapeutics | DEFA14A:其他
Eliem Therapeutics | 8-K:重大事件
Eliem Therapeutics | 4:持股变动声明-高管 Morisset Valerie
Eliem Therapeutics | S-8:员工福利计划证券登记
Eliem Therapeutics | 10-K:年度报表
Eliem Therapeutics | 4:持股变动声明-高管 Pimblett Emily
Eliem Therapeutics | 8-K:重大事件
Eliem Therapeutics | SC 13D/A:超过5%持股股东披露文件(修正)-RA Capital Management, L.P.(47.5%),Peter Kolchinsky(47.5%)等
Eliem Therapeutics | 4:持股变动声明-高管 Morisset Valerie
Eliem Therapeutics | SC 13G/A:超过5%持股股东披露文件(修正)-Braden M Leonard(8.5%),BML Investment Partners, L.P.(7.9%)
Eliem Therapeutics | SC 13D/A:超过5%持股股东披露文件(修正)-RA Capital Management, L.P.(47.7%),Peter Kolchinsky(47.7%)等
Eliem Therapeutics:2023财年三季报
Eliem Therapeutics | SC 13D/A:超过5%持股股东披露文件(修正)
暂无数据